Amundi Summit Therapeutics Inc. Transaction History
Amundi
- $275 Billion
- Q4 2024
A detailed history of Amundi transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Amundi holds 58 shares of SMMT stock, worth $1,239. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58Holding current value
$1,239% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
84.5MCall Options Held
1.97MPut Options Held
2.86M-
Baker Bros. Advisors LP New York, NY24.4MShares$522 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$249 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$169 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$140 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$120 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.3B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...